Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13225045 | 0.88 | POLB (0.51) | POLBALDH1A1TSHRSMN1; SMN2HTT | |
| SCHEMBL2863284 | 0.74 | POLB (0.51) | POLBALDH1A1TSHRSMN1; SMN2HTT | |
| SCHEMBL2861973 | 0.72 | POLB (0.49) | POLBALDH1A1TSHRSMN1; SMN2HTT | |
| SCHEMBL3501205 | 0.69 | P2RX7 (0.31) | POLB | |
| SCHEMBL3502653 | 0.68 | KDR (0.35) | KMT2A | |
| SCHEMBL3501861 | 0.67 | POLB (0.81) | POLBALDH1A1TSHRSMN1; SMN2HTT | |
| SCHEMBL17208549 | 0.66 | ALDH1A1 (1.00) | POLBALDH1A1TSHRSMN1; SMN2HTT | |
| SCHEMBL16589868 | 0.65 | CYP2C19 (0.69) | POLBALDH1A1TSHRSMN1; SMN2HTT | |
| SCHEMBL4730919 | 0.65 | POLB (0.58) | POLBALDH1A1TSHRSMN1; SMN2HTT | |
| SCHEMBL7011026 | 0.63 | TSHR (0.74) | POLBALDH1A1TSHRSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349865-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2200612-B1 | INHIBITORS OF JANUS KINASES | SCHERING CORP (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20100197634-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197634-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | POLB 3002/4885ALDH1A1 3244/4885TSHR 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.